| Nov 14 |
Marker Therapeutics GAAP EPS of -$0.26, revenue of $1.93M
|
| Nov 14 |
Marker Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates
|
| Oct 23 |
US Penny Stocks To Consider In October 2024
|
| Oct 22 |
Marker Therapeutics price target raised to $19 from $11 at Ladenburg
|
| Sep 26 |
AML cell therapy trials to watch in 2024 targeting GvHD
|
| Aug 28 |
Korro Announces Addition of Industry Veteran Katharine Knobil to and Resignation of David Lucchino From Its Board of Directors
|
| Aug 15 |
Marker Therapeutics GAAP EPS of -$0.25 beats by $0.24, revenue of $1.17M
|
| Aug 14 |
Marker Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates
|
| Aug 12 |
Marker Therapeutics gets $2M NIH grant for MT-601 Phase 1 study
|
| Aug 12 |
Marker Therapeutics Awarded $2 Million Grant from NIH in Support of Phase 1 Study Investigating MT-601 in CAR-Relapsed Patients with Non-Hodgkin’s Lymphoma
|
